Short answer
Stryker Corporation (SYK) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $6.5B (up 7.6% year over year) with net income of $753M.
Q3 2026 key financials · XBRL
- Revenue
- $6.5B
- +7.6% YoY · −1.0% QoQ
- Net income
- $753M
- −12.3% YoY · −41.0% QoQ
- Operating margin
- 15.9%
- Gross margin
- 65.2%
- EPS (diluted)
- $1.96
- −11.7% YoY · −40.6% QoQ
Source: XBRL data from the Stryker Corporation (SYK) Q3 2026 10-Q on SEC EDGAR. USD.
Stryker Corporation Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $6,520M, up 7.7% YoY from $6,057M, driven by increased unit volume
- Operating margin 15.9% vs 18.7% YoY, adjusted margin 26.2% vs 25.6%
- Best segment: MedSurg and Neurotechnology sales up 9.2%, margin 28.7% vs 26.1%
- Worst segment: Orthopaedics sales up 5.7%, margin 31.2% vs 32.4%
- Operating cash flow $3,303M vs $2,901M; $1,000M debt repayment, $1,000M share repurchases, dividends
- Peripheral Vascular supply constraints and slower recovery triggered a $293M goodwill impairment charge
Risk Factors
- No material changes to 2025 Form 10-K risk factors
- No material changes from March 31, 2026 Form 10-Q risk factors
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Stryker Corporation quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.